pentobarbital will decrease the level or effect of roflumilast samhälle affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not recommended; stark cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast knipa may reduce the therapeutic effectivenesspentobarbital decreases levels of panobinosta